NCT03970447 2026-04-22
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
Clinical Trials
15 trialsNCT02152982 2026-04-13
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT06105619 2026-01-20
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Beijing Pearl Biotechnology Limited Liability Company
Phase 2/3 Active not recruiting
NCT07349693 2026-01-20
Cerebraca-02/3
Everfront Biotech Co., Ltd.
Phase 2/3 Not yet recruiting
NCT05669820 2026-01-09
AFGB2
Skane University Hospital
Phase 2/3 Recruiting
NCT04250922 2025-11-20
CLINGLIO
Laminar Pharmaceuticals
Phase 2/3 Active not recruiting
NCT03548571 2024-04-03
DEN-STEM
Oslo University Hospital
Phase 2/3 Recruiting
NCT03008148 2021-05-11
Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
Johnpro Biotech, Inc.
Phase 2/3 Unknown
NCT03025893 2021-04-19
STELLAR
Amsterdam UMC, location VUmc
Phase 2/3 Unknown
NCT02678975 2021-03-18
Disulfiram in Recurrent Glioblastoma
Sahlgrenska University Hospital
Phase 2/3 Completed
NCT04105374 2020-03-24
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
NRG Oncology
Phase 2/3 Withdrawn
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT01759810 2017-10-12
Proteome-based Personalized Immunotherapy of Glioblastoma
NeuroVita Clinic
Phase 2/3 Unknown
NCT01961934 2016-09-28
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
Phoenix Molecular Imaging
Phase 2/3 Withdrawn
NCT01308632 2011-03-04
Metronomic Temozolamide in Patients With Recurrent Glioblastoma
Grupo Español de Investigación en Neurooncología
Phase 2/3 Unknown